Conforti, Valeria A.De Avila, David M.Curnmings, Nada S.Zanella, RicardoWells, Kenny J.Uelker, HasanReeves, Jerry J.2025-05-102025-05-1020080264-410X10.1016/j.vaccine.2007.12.0102-s2.0-38649117278https://doi.org/10.1016/j.vaccine.2007.12.010https://hdl.handle.net/20.500.14720/11845Ulker, Hasan/0000-0002-7776-3925; Zanella, Ricardo/0000-0003-1449-6708This study compared: (1) Freund's complete adjuvant and CpG oligodeoxynucleotide (ODN) 2006 in water-in-oil emulsion as adjuvants; and (2) increasing doses of a recombinant ovalbumin-LHRH (ova-LHRH) fusion protein as an antigen for a contraceptive vaccine. Treatment groups (n = 8 heifers/group) were: one untreated control group; five groups receiving CpG ODN with different doses of ova-LHRH (1.5; 2.3; 3.4; 5.1; and 7.6 mg); and one group receiving 3.4 mg ova-LHRH in Freund's. Heifers were immunized at weeks 0 and 14. Ail vaccine treatments caused gonadal regression and estrus suppression. CpG ODN is a suitable replacement for Freund's for LHRH immunization. (c) 2007 Elsevier Ltd. All rights reserved.eninfo:eu-repo/semantics/closedAccessLhrh ImmunizationCpg OdnFreund'S AdjuvantArticle267Q2Q290791318201806WOS:000253580700007